Introduction {#s0001}
============

An emerging paradigm in the treatment of cancer is to harness the individual\'s immune system to actively participate in the eradication of tumor cells. When successful, the development of an adaptive immune response to tumor-expressed antigens results in long-term tumor cell surveillance and translates into a durable clinical response. One promising pathway to evoke an innate immune response is through TLR8 activation. Activation of TLR8 in endosomal compartments of monocytes and myeloid dendritic cells (mDC) stimulates the release of distinct inflammatory mediators, including Th1-polarizing cytokines.[@cit0001] The pathway increases expression of costimulatory molecules on antigen presenting cells (APC), facilitating more effective presentation of tumor-expressed antigens to responsive T cells ([Fig. 1](#f0001){ref-type="fig"}). TLR8 agonists also enhance NK cell function, leading to an augmented antibody-dependent cell cytotoxicity (ADCC) and the production of IFNγ.[@cit0004] Figure 1.Motolimod is a selective TLR8 agonist that activates myeloid dendritic cells (mDC), resulting in the production of mediators that recruit and activate other inflammatory cells in the tumor microenvironment. Additionally, motolimod increases NK mediated antibody-dependent cell-mediated cytotoxicity (ADCC), and augments the presentation of tumor-derived antigens to the adaptive immune system.

Motolimod (VTX2337) is a potent and selective TLR8 agonist in clinical development as an immunotherapy for multiple cancer types. This therapeutic approach relies on robust activation of the immune system, yet there is the perception that cancer patients have weak immune systems due to repeat cycles of immunosuppressive chemotherapy,[@cit0005] advanced age and/or deregulated immune function related to the malignancy. For example, tumors can exert negative effects on the immune system through the release of either soluble mediators[@cit0006] or expression of immunomodulatory cell surface antigens.[@cit0008] To address these concerns, a series of investigations, including clinical studies, have fully characterized motolimod activity in advanced-stage cancer patients.

TLR8 activation in advanced cancer patients {#s0002}
===========================================

In this study,[@cit0010] we show that motolimod activation of peripheral blood monocytes (PBMCs) from healthy volunteers induces a specific set of cytokines and chemokines. Consistent with the hypothesis that TLR8 activation facilitates the development of tumor-directed adaptive immune responses, motolimod induced Th1 polarizing cytokines, IL-12p70, TNF-α and IFNγ, in addition to an array of other cytokines and chemokines. To translate motolimod *in vitro* activity into a meaningful measure of immune activation, cynomolgus monkeys were administered escalating dose levels of motolimod. Generally, plasma analytes with the greatest dynamic response to increasing doses of motolimod were a subset of analytes induced to high levels in TLR8 activated human blood. While not all mediators induced in motolimod activated PBMC appear in plasma, this was expected. The production, consumption, and clearance of cytokines/chemokines *in vivo* is a highly dynamic process, leading to large changes in plasma levels over time. However, the collective results from nonclinical studies provided a framework to assess qualitative and quantitative features of the motolimod pharmacodynamic response in humans.

In the initial clinical study of motolimod in late-stage cancer patients doses of 2.0, 2.8 and 3.9 mg/m^2^ induced dose-related increases in plasma levels of multiple cytokines and chemokines. Most of these responsive mediators had been identified as biomarkers of motolimod activity in human PBMCs and motolimod-dosed cynomolgus monkeys. In a subsequent study, a 2.5 mg/m^2^ motolimod dose was given to healthy volunteers to characterize both the pharmacokinetic and pharmacodynamic response to motolimod. The 2.5 mg/m^2^ dose was considered safe, yet pharmacologically active. In these subjects, motolimod induced significant changes in the same array of analytes that were elevated in the plasma of advanced-stage cancer patients, with few exceptions. Overall, the magnitude of the increase in mediator levels in late-stage cancer patients administered 2.0 and 2.8 mg/m^2^ were comparable to healthy volunteers who received a dose of 2.5 mg/m^2^. For cancer patients who received the 3.9 mg/m^2^ dose of motolimod, the mediator response was considerably more robust than for healthy volunteers dosed at 2.5 mg/m^2^, indicating the response in cancer patients did not plateau.

The pharmacokinetic profile for healthy volunteers given a 2.5 mg/m^2^ motolimod dose was highly comparable to that observed in cancer patients at doses of 2.0--2.8 mg/m^2^. Therefore, changes in metabolism and subsequent clearance of motolimod due to concomitant medications or the poor health of cancer patients were not a complication when comparing the level of immune activation to that of healthy volunteers.

Our study concludes that late-stage cancer patients are highly sensitive to TLR8 activation by motolimod. As predicted by nonclinical studies and confirmed by comparison to the response in healthy volunteers, tumor-mediated immune suppression, increased age, and prior treatment history with cytotoxic agents, do not moderate the TLR8 response. This demonstration of robust immune activation in cancer patients has led to the initiation of additional clinical studies designed to determine if motolimod can augment the effectiveness of some standard of care oncology treatments. TLR8 activation is expected to enhance tumor-directed immune responses to "antigenic" tumor cell death mediated by anthracyclines, which are commonly used in the treatment of ovarian cancer. TLR8 activation of NK cells can augment the ADCC activity of approved mAb therapies such as cetuximab, which is used in the treatment of squamous cell carcinoma of the head and neck (SCCHN). Thus, motolimod is being assessed in randomized, placebo controlled Phase 2 clinical studies of ovarian cancer and SCCHN to determine if it can increase the effectiveness of these standard treatments.
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